Industry slams FDA draft guidance on biosimilarity

Industry groups BIO and PhRMA, as well as biotech company Genentech, are taking issue with US FDA draft guidance  that is designed to help companies design and use clinical pharmacology studies to help prove that a developing biosimilar is similar to its reference product.

READ AT